Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPM 962 (rotigotine) Dose-ranging Study in Parkinson's Disease
NCT01634243Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2005
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rotigotine in Parkinson's disease (PD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Maintenance Dose of SPM 962 at 12 weeks. Started Jan 2005; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01634243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01634243.